Quantcast
Home > Quotes > ABEOW
ABEOW

Abeona Therapeutics Inc. Warrant (ABEOW) Quote & Summary Data

$4.5901
*  
unch
unch
Get ABEOW Alerts
*Delayed - data as of Dec. 11, 2018  -  Find a broker to begin trading ABEOW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ABEOW After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
Today's High / Low
N/A / N/A
Share Volume
0
50 Day Avg. Daily Volume
N/A
Previous Close
$ 4.5901
52 Week High / Low
$ 16 / $ 3.1799
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
0
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $4.5901 is 44.35% Higher than the 52 week low.

Intraday Last 52 Weeks
High: N/A $ 16
 Low: N/A $ 3.1799

Company Description (as filed with the SEC)

Abeona Therapeutics Inc. (together with our subsidiaries, "we," "our," "Abeona" or the "Company") is a Delaware corporation. We are a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Our lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). We are also developing ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases.  ... More ...  

Nasdaq Official Price

Open Price:
N/A
Open Date:
N/A
Close Price:
N/A
Close Date:
N/A

Research Brokers before you trade

Want to trade FX?

Analyst Info